Cannassure Therapeutics Ltd
TASE:CSURE
Intrinsic Value
CannAssure Therapeutics Ltd. engages in the cultivation, development, and distribution of medical cannabis products. [ Read More ]
The intrinsic value of one CSURE stock under the Base Case scenario is 222.13 ILS. Compared to the current market price of 1 610 ILS, Cannassure Therapeutics Ltd is Overvalued by 86%.
Valuation Backtest
Cannassure Therapeutics Ltd
Run backtest to discover the historical profit from buying and selling CSURE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cannassure Therapeutics Ltd
Current Assets | 16.7m |
Cash & Short-Term Investments | 174k |
Receivables | 4.8m |
Other Current Assets | 11.8m |
Non-Current Assets | 23.9m |
PP&E | 22.9m |
Intangibles | 985k |
Current Liabilities | 25.8m |
Accounts Payable | 6.4m |
Short-Term Debt | 14m |
Other Current Liabilities | 5.3m |
Non-Current Liabilities | 16.2m |
Long-Term Debt | 16.2m |
Other Non-Current Liabilities | 22k |
Earnings Waterfall
Cannassure Therapeutics Ltd
Revenue
|
33.8m
ILS
|
Cost of Revenue
|
-30.5m
ILS
|
Gross Profit
|
3.3m
ILS
|
Operating Expenses
|
-6.1m
ILS
|
Operating Income
|
-2.8m
ILS
|
Other Expenses
|
-2.7m
ILS
|
Net Income
|
-5.5m
ILS
|
Free Cash Flow Analysis
Cannassure Therapeutics Ltd
CSURE Profitability Score
Profitability Due Diligence
Cannassure Therapeutics Ltd's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Cannassure Therapeutics Ltd's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
CSURE Solvency Score
Solvency Due Diligence
Cannassure Therapeutics Ltd's solvency score is 19/100. The higher the solvency score, the more solvent the company is.
Score
Cannassure Therapeutics Ltd's solvency score is 19/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CSURE Price Targets Summary
Cannassure Therapeutics Ltd
Shareholder Return
CSURE Price
Cannassure Therapeutics Ltd
Average Annual Return | -18.51% |
Standard Deviation of Annual Returns | 45.79% |
Max Drawdown | -91% |
Market Capitalization | 123.9m ILS |
Shares Outstanding | 76 957 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CannAssure Therapeutics Ltd. engages in the cultivation, development, and distribution of medical cannabis products. The firm has two main business activities; Yielding real estate and real estate investments in which the Company, directly and through its subsidiaries; locates, purchases, rents, upgrades and manages real estate. The firm and its subsidiaries have investments and property rights in Germany, Serbia, India, Kazakhstan, Latvia and Israel.
Officers
The intrinsic value of one CSURE stock under the Base Case scenario is 222.13 ILS.
Compared to the current market price of 1 610 ILS, Cannassure Therapeutics Ltd is Overvalued by 86%.